135 results about "Intestinal epithelium" patented technology

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.

The invention discloses an application of a Piezo1 inhibitor in preparation of a medicine for treating necrotizing enterocolitis. The Piezo1 inhibitor can be applied in preparation of the medicine for treating the necrotizing enterocolitis. The Piezo1 inhibitor can also be applied to preparation of drugs for relieving NEC intestinal epithelial barrier injury. The Piezo1 inhibitor can also be applied to preparation of drugs for reducing calcium influx in intestinal epithelial cells and calcium / calmodulin dependent protein kinase activity. The application has the beneficial effects that the effect and mechanism of the Piezo1 for regulating and controlling the calcium ion influx and promoting the NEC severity degree by the calcium / calmodulin dependent protein kinase activity level are discussed for the first time from multiple aspects of animals, tissues, cells, molecules and the like, and the effect and mechanism of the activated intestinal epithelial cell Piezo1 in NEC inflammatory injury and barrier repair are clarified for the first time; the knockout of the gene can improve the NEC severity of mice, and a new intervention target is provided for clinical treatment.

The invention belongs to the technical field of probiotic products, and particularly relates to lactobacillus rhamnosus JM039 as well as a composition and application thereof. The preservation number of the lactobacillus rhamnosus JM039 is GDMCC No: 64409. The lactobacillus rhamnosus JM039 is a lactobacillus rhamnosus strain. The composition is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum JY039 and lactobacillus rhamnosus JM039, and is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum The combined bacteria of the six probiotics can improve the levels of anti-inflammatory factors and intestinal epithelium tight junction proteins and reduce the levels of proinflammatory factors and claudin-2 mRNA, so that the intestinal microenvironment homeostasis and intestinal barrier integrity are maintained through double regulation of inflammatory factors and tight junction proteins, and necrotizing enterocolitis can be relieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bifidobacterium breve and lactoferrin in preparation of products for regulating intestinal flora or resisting bacterial infection. The invention provides application of Bifidobacterium breve HH079 with the preservation number of GDMCC No: 64216 and lactoferrin in preparation of a product for regulating intestinal flora or a product for resisting bacterial infection, and the Bifidobacterium breve HH079 and the lactoferrin are combined and synergistically used for resisting the bacterial infection. The composition can reverse weight loss, colon shortening, bacterial load increase and colon epithelium injury caused by bacterial infection, can significantly inhibit the level of proinflammatory cytokines, promote the expression of anti-inflammatory cytokines, can significantly increase the concentration of acetic acid and propionic acid in excrement of infected mice, can generate positive regulation on intestinal flora, and can inhibit bacterial infection. Good application prospects are shown in regulation of intestinal flora and bacterial infection resistance.

The invention discloses a construction method and application of a GSDMB intestinal epithelium specific knock-in mouse model. The construction method comprises the following steps: (1) designing gRNA according to an ROSA26 gene, constructing a Donor vector containing a GSDMB gene, introducing the gRNA and the Donor vector and Cas mRNA into a fertilized egg of a receptor mouse, transplanting the fertilized egg and Cas mRNA into a pseudopregnant mouse body for reproduction, and screening out a GSDMB gene knock-in F0-generation mouse; (2) mating and breeding the F0 generation mouse and a wild type mouse, and screening out an F1 heterozygote mouse with GSDMB knocked in; (3) carrying out inbreeding propagation on the F1 heterozygote mouse, and screening out an F2 homozygote mouse in which GSDMB is knocked; (4) the F2 homozygote mouse and the intestinal epithelium specific Vilin-Cre transgenic mouse are subjected to mating breeding, and a heterozygote mouse with GSDMB intestinal epithelium specific knock-in is screened out; and (5) carrying out inbreeding propagation on the heterozygote mouse with the GSDMB intestinal epithelium specific knock-in, and screening out the homozygote mouse with the GSDMB intestinal epithelium specific knock-in.

The invention provides an organoid chip for screening micro-ecological drugs as well as application and a preparation method of the organoid chip, and relates to the technical field of biological medicines. The invention provides a chip integrating intestinal epithelium, a prostate cancer organ and a bladder cancer organ, which is used for researching how microecological preparations, such as probiotics, metabolites and the like, affect tumor microenvironment and immunotherapy effects. The chip can simulate interaction of intestinal tract-tumor axis, and provides an in-vitro evaluation system for precise tumor immunotherapy.

The invention discloses a feed additive for preventing broiler necrotic enteritis, a preparation method and application, and relates to the technical field of feed. Comprising the following raw materials in parts by weight: 15-30 parts of plant essential oil, 40-60 parts of deoxycholic acid, 10-20 parts of vitamin D310, 3-8 parts of protein zinc, 2-6 parts of saccharomyces cerevisiae and 1-5 parts of zeolite powder. The feed additive provided by the invention is clear in component, stable in property, convenient to operate and control, easy to realize industrial production, and convenient to popularize and apply. By adopting the feed additive provided by the invention, the integrity of the intestinal epithelial barrier can be improved, the intestinal flora structure can be improved, the immunity of the organism can be improved, and necrotic enteritis of broilers can be effectively prevented.

The present: invention relates to a pharmaceutical composition comprising curcumin and ginsenoside, and a formulation comprising same. Using curcumin and ginsenoids according to the present invention in combination with butyric acid and sucralfate restores cell growth, mobility, and endothelial cell tube-forming by ability reduced irradiation, and inhibits an inflammatory response induced in macrophages by LPS treatment. In addition, it was confirmed that, when an irradiated mouse is topically treated with the formulation according to the present invention comprising the compounds, intestinal epithelial tissue damaged by irradiation is restored and the expression of inflammatory cytokines in the intestinal tissue is suppressed. Furthermore, a mixture of a ginseng extract and a turmeric extract also restored the intestinal epithelial tissue damaged by irradiation. Therefore, the pharmaceutical composition comprising curcumin, ginsenoid, butyric acid, and sucralfate, or the pharmaceutical composition comprising a mixture of a ginseng extract and a turmeric extract, and the formulation according to the present invention comprising same can be utilized for treating radiation proctitis.

The application discloses a pachymic acid medicine composition for preventing and treating ulcerative colitis and application thereof, and relates to the technical field of medical application. The composition is prepared from the following components in parts: pachymic acid 100-500 parts, carboxymethyl cellulose solution 10-100 parts, medicinal adjuvant 10-120 parts, synergistic adjuvant 10-100 parts, solvent 10-50 parts, and purified water 100-120 parts. The pachymic acid is used as a clear monomer active ingredient to prepare a medicine for preventing and treating ulcerative colitis. Compared with the existing compound, extract or multi-component combination technical scheme, the application has the characteristics of clear active ingredient, relatively clear efficacy basis, convenient quality control and subsequent development. It is clear that the ulcerative colitis can be prevented and treated by inhibiting the cGAS-STING and NF-κB signal pathways, reducing the damage of the colon epithelial cells, inhibiting the release of pro-inflammatory factors, repairing the damaged intestinal mucus barrier and intestinal epithelial barrier, regulating the apoptosis balance of intestinal cells, and enhancing the antioxidant activity of the intestinal tract. The application plays a role in preventing and treating ulcerative colitis from multiple targets such as inflammation inhibition, barrier repair and antioxidant.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

The present invention provides a kind of radix schizonepetae extract for treating ulcerative colitis and its preparation method and application, and relates to the field of biomedicine technology. The preparation method of the radix schizonepetae extract of the present invention comprises: soaking radix schizonepetae in water, heating and boiling, condensing and refluxing, filtering, and collecting the filtrate, which is the radix schizonepetae extract. The radix schizonepetae extract of the present invention can reduce collagen deposition and intestinal epithelial cell apoptosis in the colon epithelium of ulcerative colitis, has the effect of downregulating the abnormally high expression of genes and proteins such as N-cadherin, IntegrinA1, Vinculin, TGF-β2, Srcin, etc. in the colon tissue of ulcerative colitis, reduces colon fibrosis and inflammatory damage, protects the barrier function of the colon epithelium, and has the effect of inhibiting the overexpression of Wnt 5A / B and β-Catenin proteins caused by DSS, and alleviates colon fibrosis, thereby achieving the effect of treating ulcerative colitis and alleviating colon fibrosis.

The invention relates to a nutritional composition for infants, for children as well as a medical nutritional composition, comprising human milk oligosaccharides and Bifidobacterium breve. The invention further relates to the use of said nutritional composition for strengthening the gut epithelial defense and / or the gut barrier function.

Disclosed herein is a custom platform called NSC-seq that can be used for cell lineage and cell division tracking in a temporal fashion but also with single-cell resolution. With simultaneous integration of single-cell transcriptomics with lineage barcoding and temporal recording information, NSC-seq facilitates the generation of multidimensional datasets for elucidating functional heterogeneity and clonal events in vivo. We apply this platform (i) to decipher lineage branching of mouse embryonic development, (ii) to record clonal dynamics of the adult intestinal epithelium, and (iii) to track clonal composition of the mouse intestinal tumors. In addition, we apply NSC-seq to assess a comprehensive gene expression phenotype for individual gene knockout at the single-cell level using existing whole-genome CRISPR knockout screening plasmid libraries. Overall, NSC-seq enables in vivo temporal recording of mammalian development and cancer at single-cell resolution.

The invention relates to the technical field of medicines, and provides a PMC nano-enzyme and a preparation method thereof. The PMC nano-enzyme comprises: a core layer, wherein the core layer comprises oxygen atoms, phosphate ions and a polyoxometallate nano-cluster of a first transition metal element; at least part of the coating layer is fixed on the outer surface of the core layer, and the coating layer is formed through coordination between second transition metal and oxygen atoms on the core layer; wherein the first transition metal element comprises Mo; the second transition metal element includes Mn, and the coating layer includes a CO donor for controlling CO gas release. According to the PMC nano-enzyme disclosed by the invention, the polyoxometallate nano-cluster can be combined with a CO gas therapy to synergistically treat IBD, on the basis of endowing the nano-cluster with anti-inflammatory and intestinal epithelial barrier repair promoting functions, the catalytic activity is enhanced, and CO is released in an active oxygen overexpression environment, so that oxidative stress is relieved, inflammatory response is inhibited, intestinal immune balance is recovered, and the effect of treating IBD is achieved. The repair of mucosal injury is promoted.

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and / or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

The invention discloses an application of a compound indoleacrylic acid in preparation of a medicine for regulating intestinal epithelial necrotic apoptosis and preventing and treating neonatal necrotic enterocolitis, and belongs to the technical field of medicines. The compound indoleacrylic acid is used for relieving related pathological characteristics of NEC mice, including increasing the survival rate of the NEC mice, increasing the body weight of the NEC mice, reducing small intestine shortening, reducing disease activity index scores and relieving histological injury, and in addition, the indoleacrylic acid can inhibit intestinal epithelium necrotic apoptosis of the NEC mice to relieve and relieve disease symptoms; the compound indole acrylic acid is used for preparing a medicine for regulating intestinal epithelial necrotic apoptosis and preventing intestinal inflammation and intestinal necrosis.

The invention relates to the technical field of natural medicines, and particularly discloses application of a curcuma wenyujin extract and an enema thereof in treating ulcerative colitis. Experiments show that the curcuma wenyujin extract can repair intestinal epithelial barrier, relieve oxidative stress of intestinal epithelium and reduce generation of neutrophil ROS (reactive oxygen species), and through the synergistic effect of multiple ways, the disease progress of ulcerative colitis is remarkably relieved in vivo, the intestinal barrier function is enhanced, and inflammatory response is controlled. Therefore, the curcuma wenyujin extract has great potential in preparation of medicines for treating ulcerative colitis. The application range of the curcuma wenyujin extract is widened, an experimental basis is provided for the curcuma wenyujin extract and the enema thereof to treat clinical ulcerative colitis, and the curcuma wenyujin extract and the enema thereof have a good clinical transformation prospect.

The invention discloses a marker for diagnosing intestinal epithelial barrier injury induced by uremic toxin and application of the marker, and belongs to the technical field of biomedicine. Human colon cancer cells (Caco-2) are adopted to establish intestinal epithelial injury models under different urea treatment conditions, and the optimal concentration and time are screened through CCK-8 and immune blot. According to the present invention, RT-qPCR is adopted to detect the expression of lncRNANEAT1 and miR-122-5p, Westernblot and an immunofluorescence method are adopted to detect the expression of tight junction proteins Occludin, ZO-1 and Claudin-1, fluorescein sodium is adopted to detect the cell para-permeability of an intestinal epithelial injury model, and the combination of miR-122-5p with lncRNANEAT1 and Occludin is detected through bioinformatics analysis and dual-luciferase reporter gene analysis; the result shows that the lncRNANEAT1 can be used for protecting intestinal epithelial barrier injury induced by uremia toxin by regulating the miR-122-5p / Occludin axis. The discovery reveals an action mechanism of the lncRNANEAT1 in uremia toxin induced intestinal epithelial barrier injury, and provides a new thought and method for reducing complications of uremia patients and improving life quality.

The present invention discloses the application of cyanidin-3,5-O-diglucoside in the preparation of a drug for treating colitis and colonic fibrosis. The present invention has found that after treatment with cyanidin-3,5-O-diglucoside, the clinical symptoms of colitis and colonic pathological damage can be improved, the level of inflammatory factors in serum of chronic colitis induced by DSS can be reduced, the intestinal epithelial permeability can be reduced and the mucosal barrier damage can be repaired, the level of oxidative stress in the body of colitis can be improved, and the degree of colonic fibrosis can be reduced, and the normal function of the colon can be protected. Compared with the therapeutic effect of the positive drug 5-aminosalicylic acid, there is no significant difference in multiple indicators, and cyanidin-3,5-O-diglucoside has higher safety and lower side effects.

The present invention relates to an intestinal epithelium model faithfully reproducing the pathophysiological mechanisms observed in vivo in the context of an inflammatory state of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages.The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin (IL-6) at a concentration greater than 100 pg / mL, and interleukin 8 (IL-8) at a concentration greater than 150 pg / mL, and the cells contained in the second compartment produce tumor necrosis factor α (TNF-α) at ​​a concentration greater than 40 pg / mL and interleukin 1β (IL-1β) at a concentration greater than 90 pg / mL. The present invention also relates to the method for obtaining this model as well as to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop inflammation upon increase in permeability or to verify the restoration of permeability and the mucus layer.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

The present disclosure relates to a stem cell-drug carrier including a melatonin-containing drug carrier and a stem cell, and more particularly, to a use of the stem cell for the treatment of intestinal epithelial damage disease and inflammatory bowel disease. According to the present disclosure, it was confirmed that the stem cell-drug carrier continuously released PGE2 and had excellent revival stem cell induction ability. This means that the stem cell-drug carrier of the present disclosure has an excellent intestinal epithelium regeneration effect, and the stem cell-drug carrier of the present disclosure can be used in various fields of treatment of intestinal damage disease and inflammatory bowel disease.

The present invention belongs to the field of biomedicine technology, and specifically relates to the application of Bifidobacterium breve in cooperating with lactoferrin in the preparation of products for regulating intestinal flora or resisting bacterial infection. The present invention provides Bifidobacterium breve ( Bifidobacterium breve ) The application of HH079 in conjunction with lactoferrin in the preparation of products for regulating intestinal flora or anti-bacterial infection products. The present invention combines Bifidobacterium breve HH079 with lactoferrin, which are synergistically used to fight bacterial infection. It can reverse the weight loss, colon shortening, increased bacterial load and colon epithelial damage caused by bacterial infection, significantly inhibit the level of pro-inflammatory cytokines, promote the expression of anti-inflammatory cytokines, significantly increase the concentration of acetic acid and propionic acid in the feces of infected mice, and produce positive regulation on intestinal flora, showing good application prospects in regulating intestinal flora and anti-bacterial infection.

The invention relates to the field of hair growth nutrients, and discloses a nutrient composition for promoting hair growth and a preparation method thereof, the composition comprises a basic hair growth nutrient group and an absorption-promoting synergistic group; the basic hair growth nutrition group comprises the following components in parts by weight: 0.3-0.8 part of ferrous lactate, 2-5 parts of zinc gluconate, 5-8 parts of magnesium stearate, 3-8 parts of a coating material and 17-25 parts of milk mineral salt; the absorption-promoting synergistic group comprises the following components in parts by weight: 0.2-1.5 parts of a black pepper extract, 2-10 parts of lecithin and 2-8 parts of casein phosphopeptides, the black pepper extract and the lecithin are firstly released, an intestinal epithelium channel is opened by utilizing a biological penetration promoting effect, and a pre-permeation state is established; the subsequently released CPP is complexed with divalent metal ions in intestinal juice to prevent precipitation, so that the CPP is synchronously and rapidly absorbed through a pre-opened channel, and the problems of competitive antagonism and difficult absorption of high-dose minerals are effectively solved.

To provide a composition that can suppress the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease. [Solution] An agent containing human milk oligosaccharides that suppresses the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease.

A composition comprising an ingredient that is effective for inducing autophagy in intestinal epithelial cells and intestinal epithelial stem cells and can be ingested at ease on a daily basis is provided. A composition for inducing autophagy, the composition comprising bacterial cells of a lactic acid bacterium belonging to the family Lactobacillaceae is provided. The lactic acid bacterium is preferably a lactic acid bacterium belonging to any of the genera Lactiplantibacillus, Lactobacillus, Lacticaseibacillus, Companilactobacillus, and Limosilactobacillus.

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The invention provides an FcRn-targeted Brucella multi-epitope nano vaccine, which can realize long-term protection, shows continuous immune memory, has high-frequency hair-growing central B cells (GCB), follicular helper T cells (TFH) and central memory T cells (TCM), and ensures long-term immune surveillance; even six months after immunization, the serum IgG titer is still obviously higher than that of a control group; efficient antigen delivery can be achieved, specifically, a chitosan-based nano-particle system is adopted, and antigen protection and intestinal epithelium uptake are enhanced through FcRn targeted ligand modification; the delivery efficiency can be improved by 10 times, and the gastrointestinal mucosal barrier is overcome; in addition, rapid immune starting can be achieved, multi-dimensional immune response is induced within 14 days after final immunization, and rapid protection is provided for resisting brucella infection.

The invention discloses a fusion protein, a pharmaceutical composition and application. The fusion protein is formed by fusing uricase and polypeptide with mucoprotein binding property. The original uricase activity of the fusion protein is not affected, the binding property of the fusion protein and II-type mucoprotein covering the intestinal epithelium mucous layer is remarkably improved, and the fusion protein can be orally taken to treat diseases or disorders related to increase of uric acid amount, such as hyperuricemia, hyperuricemia and gout.